Fig. 7: PDZK1 sensitizes TNBC cells to erlotinib in vitro and in vivo.
From: PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway
A, B PDZK1-WT, but not PDZK1-MT_S2,3 overexpression sensitised TNBC cells to erlotinib in inhibiting EGFR-mediated signalling pathway. WB analysis of phosphorylation levels of EGFR and its downstream molecules in TNBC cells stably expressing empty vector or PDZK1-WT or PDZK1-MT_S2,3 combined with erlotinib treatment. All WBs are representative of one of three independent experiments (A, B). PDZK1 overexpression sensitised TNBC cells to erlotinib in inhibiting cell proliferation (C, D), colony formation (E), migration (F, G) and invasion (H) abilities. The photo (I), the volume (J) and the weight (K) of xenograft tumours, treated with PDZK1 overexpression alone, erlotinib alone or a combination of PDZK1 overexpression with erlotinib (n = 6 mice per group). IHC results of Ki67 level (L) and EGFR/pEGFR/pERK level (M) in xenograft tumour tissues. Data are shown as mean ± SD of three independent experiments. Data were analysed by repeated measures ANOVA (C, D) and ANOVA (E–H, J–M). *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. ns, not significant.
